Related Experiment Video
Updated: Aug 6, 2026
Orthotopic Aortic Transplantation: A Rat Model to Study the Development of Chronic Vasculopathy
Published on: December 4, 2010
Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats
S M Stepkowski1, X Qu, M E Wang
1Division of Immunology and Organ Transplantation, The University of Texas Medical School at Houston, 77030, USA.
Background:
C-raf is a well-characterized serine/ threonine (Ser/Thr) protein kinase that is involved in the transduction of multiple signals of T cells. We demonstrate that the inhibition of C-raf mRNA expression prolongs heart allograft survival.
Methods:
Three 20-mer C-raf antisense oligonucleotides, each with identical sequences, were synthesized with different chemical modifications: one as a uniform phosphorothioate oligodeoxynucleotide (PS oligo), a second with a PS backbone and 2'-methoxyethyl (ME) substitutions at the 2'-sugar positions in the first and last five nucleotides, and a third with a mixed PS and phosphodiester (PD) backbone and ME modifications on the first and last five nucleotides.
Results:
Both ME-modified C-raf antisense oligos were at least 5-fold more effective than the PS C-raf antisense oligo in blocking C-raf mRNA expression in two cell lines. Similarly, each of the ME C-raf antisense oligos produced better heart allograft survival rates than did PS C-raf oligo. Furthermore, although the combination of PS C-raf antisense oligo with sirolimus (SRL) acted synergistically to extend heart allograft survival, the effect was potentiated by either of the ME-modified oligos.
Conclusions:
C-raf inhibition extends heart allograft survival, and ME-modification potentiates antisense activity.
Insights
Inhibiting C-raf kinase mRNA expression prolongs heart allograft survival. Modified antisense oligonucleotides (ASOs) significantly enhance this effect, improving outcomes in transplantation.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- C-raf is a serine/threonine protein kinase crucial for T-cell signaling.
- Inhibition of C-raf mRNA expression has been shown to extend heart allograft survival.
Purpose of the Study:
- To investigate the efficacy of C-raf antisense oligonucleotides (ASOs) in prolonging heart allograft survival.
- To evaluate the impact of chemical modifications on ASO activity and therapeutic potential.
Main Methods:
- Synthesis of three C-raf antisense oligonucleotides with varying chemical modifications: uniform phosphorothioate (PS), 2'-methoxyethyl (ME)-modified PS, and mixed PS/phosphodiester (PD) with ME modifications.
- Assessment of C-raf mRNA inhibition in cell lines.
- Evaluation of heart allograft survival rates in response to ASO treatment, with and without sirolimus (SRL).
Main Results:
- ME-modified C-raf ASOs were over 5-fold more effective than PS ASOs in inhibiting C-raf mRNA expression.
- ME-modified C-raf ASOs significantly improved heart allograft survival rates compared to PS ASOs.
- The combination of PS C-raf ASO and sirolimus showed synergistic effects, which were further potentiated by ME-modified oligos.
Conclusions:
- C-raf inhibition is a viable strategy for extending heart allograft survival.
- 2'-methoxyethyl modification of antisense oligonucleotides enhances their efficacy and therapeutic potential in transplantation.
